plse20260427_10ka.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-K/A

(Mark One)

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-34899

Pulse Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware	46-5696597
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

601 Brickell Key Drive, Suite 1080 Miami, FL	33131
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (510) 906-4600

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common Stock, par value $0.001 per share	PLSE	The Nasdaq Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Aggregate market value of registrant’s common stock held by non-affiliates of the registrant on March 31, 2026, the last business day of the registrant’s most recently completed first fiscal quarter, based upon the closing price of the registrant’s common stock on such date as reported by Nasdaq Capital Market, was approximately $394,339,817. Shares of voting stock held by each officer and director have been excluded in that such persons may be deemed to be affiliates. This assumption regarding affiliate status is not necessarily a conclusive determination for other purposes.

Number of shares outstanding of the registrant’s common stock as of March 31, 2026: 68,225,067

Auditor Name		Auditor Location		Auditor Firm ID
Deloitte & Touche LLP		San Francisco, California		PCAOB ID 34

DOCUMENTS INCORPORATED BY REFERENCE:

None.

	PART III	Page

Item 10.	Directors, Executive Officers, and Corporate Governance	4
Item 11.	Executive Compensation	12
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	20
Item 13.	Certain Relationships and Related Transactions, and Director Independence	21
Item 14.	Principal Accounting Fees and Services	22

	PART IV

Item 15.	Exhibits, Financial Statement Schedules	23

Name	Age		Position
Paul A. LaViolette		68	Co-Chairman of the Board of Directors, Chief Executive Officer and President
Robert W. Duggan		81	Co-Chairman of the Board of Directors
Maria Sainz		60	Director
Manmeet S. Soni		48	Director and Lead Independent Director
Darrin R. Uecker		60	Director and Chief Technology Officer
Richard A. van den Broek		60	Director
Mahkam Zanganeh, D.D.S.		55	Director

Name	Audit	Compensation	Nominating and Corporate Governance	Strategic Advisory Committee
Robert W. Duggan		X	X
Paul A. LaViolette⁽¹⁾	X		X	X*
Maria Sainz	X
Manmeet S. Soni	X*	X*	X*	X
Richard A. van den Broek	X	X
Mahkam Zanganeh				X
Number of meetings held during 2025	4	2	1	4

*		Chair of committee.
(1)		Mr. LaViolette was elected to our board of directors as of August 9, 2024. He was appointed as a member of our Audit Committee, Corporate Governance and Nominating Committee, and Strategic Advisory Committee in connection with his election. However, upon his appointment as our Chief Executive Officer and President on January 9, 2025, Mr. LaViolette resigned from his position as a member of these committees other than remaining as an ex officio member of the Strategic Advisory Committee as our Chief Executive Officer.

	●	outlining to our Board of Directors improvements made, or to be made, in internal accounting controls;
	●	selecting and supervising the independent auditors;

Name	Fees Earned or Paid in Cash ($)	Option Awards ($)⁽¹⁾	Total ($)
Robert W. Duggan	18,252	614,888	633,140
Paul A. LaViolette⁽²⁾	39,541	6,717,960	6,757,501
Manmeet S. Soni	267,255	364,548	631,803
Richard A. van den Broek	48,196	364,548	412,744
Mahkam Zanganeh	49,479	655,126	704,605

(1)		Amounts shown represent the aggregate grant date fair value of the option awards computed in accordance with FASB ASC Topic 718. These amounts do not correspond to the actual value that will be realized. The assumptions used in the valuation of these awards are consistent with the valuation methodologies specified in the notes to our financial statements. During fiscal year 2025, Mr. LaViolette was granted option awards with market-based and performance-based vesting conditions. The maximum potential value of Mr. LaViolette's option awards was $16,239,000, at the time of grant, assuming the highest level of performance achieved.
(2)		Mr. LaViolette was elected to our board of directors as of August 9, 2024. As previously disclosed, Mr. LaViolette was appointed as our President and Chief Executive Officer as of January 9, 2025.

Name	Aggregate Number of Stock Options, Warrants or Rights Outstanding as of December 31, 2025	Aggregate Number of Stock Options, Warrants or Rights Exercisable as of December 31, 2025
Robert W. Duggan	261,078	230,682
Paul A. LaViolette⁽¹⁾⁽²⁾	1,750,000	93,750
Manmeet S. Soni⁽²⁾	558,885	413,885
Richard A. van den Broek	270,911	250,911
Mahkam Zanganeh⁽²⁾	506,220	349,153

(1)		Mr. LaViolette was elected to our board of directors, effective as of August 9, 2024. As previously disclosed, Mr. LaViolette was appointed as our President and Chief Executive Officer, effective as of January 9, 2025.
(2)		Messrs. LaViolette and Soni and Dr. Zanganeh were each granted an option to purchase up to 200,000 shares of common stock for their service on the Strategic Advisory Committee of our Board of Directors, with each grant subject to future stockholder approval of an increase in the number of shares available to grant under the Company's Equity Incentive Plan.

Name and Principal Position	Year	Salary ($)		Bonus ($)		Option Awards ($)(1)	All Other Compensation ($)	Total ($)
Paul A. LaViolette⁽²⁾	2025	708,523		—		6,717,960	1,416	7,427,899
Chief Executive Officer and Co-Chairman	2024	—		—		—	—	—
	2023	—		—		—	—	—
	2022	—		—		—	—	—

Jon Skinner⁽³⁾	2025	366,667		56,000		2,419,035	1,298	2,843,000
Chief Financial Officer	2024	—		—		—	—	—
	2023	—		—		—	—	—
	2022	—		—		—	—	—

Darrin R. Uecker	2025	540,312		328,161		—	1,416	869,889
Chief Technology Officer and Director	2024	512,500		102,473		—	1,437	616,410
	2023	433,333		399,973	⁽⁴⁾	4,556,552	1,420	5,391,278
	2022	485,909		—		—	1,326	487,235

Kevin P. Danahy⁽⁵⁾	2025	525,000		328,161		—	1,416	854,577
Former Chief Commercial Officer	2024	512,500		102,473		1,955,188	1,437	2,571,598
	2023	433,332		399,973	⁽⁴⁾	5,030,974	1,420	5,865,699
	2022	350,038		—		1,215,760	1,203	1,567,001

Burke T. Barrett⁽⁶⁾	2025	—		—		—	—	—
Former Chief Executive Officer and Former Director	2024	327,318	⁽⁸⁾	108,510		8,700,311	1,437	9,137,576
	2023	—		—		—	—	—
	2022	—		—		—	—	—

Mitchell E. Levinson⁽⁷⁾	2025	—		—		—	—	—
Former Chief Strategy Officer and Former Director	2024	—		—		—	—	—
	2023	369,563		213,582		1,061,568	1,420	1,646,133
	2022	360,000		—		—	1,338	361,338

	Option Awards
Name	Number of Securities Underlying Outstanding Options (#)						Option Exercise Price ($/sh)		Option Expiration Date
	Exercisable			Unexercisable and Unearned
Paul A. LaViolette		75,000			125,000	⁽¹⁾		15.65	08/09/2034
		18,750			31,250	⁽²⁾		15.65	08/09/2034
		—			5,425	⁽³⁾		18.43	01/09/2035
		—			107,075	⁽³⁾		18.43	01/09/2035
		—			5,425	⁽³⁾		18.43	01/09/2035
		—			332,075	⁽³⁾		18.43	01/09/2035
		—			600,000	⁽⁵⁾		18.43	01/09/2035
		—			450,000	⁽⁵⁾		18.43	01/09/2035

Kevin P. Danahy⁽⁶⁾		75,000			25,000	⁽³⁾		6.41	02/14/2032
		25,000			25,000	⁽³⁾		6.41	02/14/2032
		312,500			112,500	⁽³⁾		1.53	09/23/2032
		100,000			25,000	⁽⁴⁾		6.41	02/14/2032
		—			25,000	⁽⁵⁾		6.41	02/14/2032
		—			500,000	⁽⁵⁾		6.44	04/29/2033
		—			200,000	⁽⁵⁾		7.08	07/12/2033
		—			460,000	⁽⁷⁾		4.38	11/01/2033

Darrin R. Uecker		195,000	⁽⁸⁾		—			30.99	06/07/2027
		187,286	⁽⁸⁾		—			30.99	06/07/2027
		54,750	⁽⁴⁾		—			24.03	03/22/2031
		37,500	⁽⁸⁾		—			10.66	05/18/2030
		—			500,000	⁽⁵⁾		6.44	04/29/2033
		—			200,000	⁽⁵⁾		7.08	07/12/2033
		—			330,000	⁽⁷⁾		4.38	11/01/2033

Jon Skinner		—			19,616	⁽³⁾		20.93	02/03/2035
		—			130,384	⁽³⁾		20.93	02/03/2035
		—			150,000	⁽⁵⁾		20.93	02/03/2035

(1)		Amounts shown represent the aggregate grant date fair value of the option awards computed in accordance with FASB ASC Topic 718. These amounts do not correspond to the actual value that will be realized by our named executive officers. The assumptions used in the valuation of these awards are consistent with the valuation methodologies specified in the notes to our financial statements. During fiscal year 2025, Messrs. LaViolette and Skinner were each granted option awards with market-based and performance-based vesting conditions. The maximum potential value of their option awards were $16,239,000 and $2,625,375, respectively, at the time of their grant, assuming the highest level of performance achieved. The potential value of each of these awards is not reflected in the table above.
(2)		Mr. LaViolette was appointed as our President and Chief Executive Officer as of January 9, 2025. He did not receive any employment compensation from us during fiscal year 2024, 2023 or 2022.
(3)		Mr. Skinner joined the Company in February 2025. He did not receive any employment compensation for fiscal year 2024, 2023 or 2022.
(4)		Reflects prepayment of the 2023 bonus potential by the Company’s Board of Directors.
(5)		Mr. Danahy served as our Chief Commercial Officer from February 2022 to October 2022 and again from January 2025 to February 2026. He served as our Chief Executive Officer from October 2022 to May 2024 and again from December 2024 to January 2025.
(6)		Mr. Barrett served as our Chief Executive Officer from May 2024 to December 2024. He did not receive any compensation for fiscal years 2022 and 2023. He only received continuing severance payments in fiscal year 2025.
(7)		Mr. Levinson’s status as a named executive officer ended in 2024 and his employment ended in 2026. Accordingly, we are only reporting the compensation he received in 2022 and 2023 in the above table.
(8)		Reflects a severance payment of $21,875.

(1)		Granted subject to future stockholder approval of an increase in the number of shares available to grant under the Company's Equity Incentive Plan.
(2)		Board service grant pursuant to the Company's Amended and Restated Outside Director Compensation Policy.
(3)		Grant consisting of 100% time-based vesting option grants.
(4)		Performance-based vesting stock option grants of which a portion of the performance criteria have been achieved.
(5)		Performance-based vesting stock option grants of which no performance criteria have been achieved.
(6)		Mr. Danahy served as our Chief Commercial Officer from January 2025 to February 2026.
(7)		Stock options will vest in full automatically upon the earlier to occur of (i) the six (6) year anniversary of the grant date, and (ii) the 1-year anniversary of a Change in Control, as defined by the Company’s 2017 Equity Incentive Plan; provided, however, that no Change in Control shall be found to exist for purposes of vesting of the Awards if the primary purpose of the persons investing in the Company is principally to provide working capital financing, and not to acquire a controlling interest in the Company, notwithstanding whether the sum of such investment, after the financing, equals or exceeds 50% of the ownership of the Company.
(8)		Fully-vested stock option grants.

Name and Address of Beneficial Owner	Number of Shares Owned⁽¹⁾		Right to Acquire Shares⁽²⁾		Total Beneficial Ownership		Percent of Class⁽³⁾
5% Stockholders:
Robert W. Duggan⁽⁴⁾		48,789,438		248,380		49,037,818		71.6	%

Named executive officers and directors:
Robert W. Duggan⁽⁴⁾		48,789,438		248,380		49,037,818		71.6	%
Paul A. LaViolette		846		122,395		123,241		*
Jon Skinner		1,556		37,500		39,056		*
Manmeet S. Soni		—		447,218		447,218		*
Liane Teplitsky		—		—		—		—
Darrin R. Uecker		284,829		474,536		759,365		1.1	%
Richard A. van den Broek		—		263,411		263,411		*
Mahkam Zanganeh, D.D.S.⁽⁵⁾		873,469		388,519		1,261,988		1.8	%
All executive officers and directors as a group (8 people)		49,950,138		1,981,959		51,932,097		74.7	%

*		Represents beneficial ownership of less than one percent.
(1)		Excludes shares that may be acquired through the exercise of outstanding stock options or the vesting of restricted stock units or other equity awards.
(2)		Represents shares issuable within 60 days after March 31, 2026 upon exercise of exercisable options or exercisable warrants to purchase common stock issued in the Company’s 2024 rights offering; however, unless otherwise indicated, these shares do not include any equity awards awarded after March 31, 2026.
(3)		For purposes of calculating the Percent of Class, shares that the person or entity had a right to acquire are deemed to be outstanding when calculating the Percent of Class of such person or entity.
(4)		Based on information obtained from Mr. Duggan. Includes shares owned by Genius Inc. and shares owned by Blazon Corporation, both of which Mr. Duggan is the sole stockholder. The number of shares of common stock beneficially owned by Mr. Duggan reported in the table above does not include the 1,094,826 shares of common stock which are beneficially owned by Mr. Duggan’s spouse, Dr. Zanganeh, and which are described in footnote 5 below. As spouses, Mr. Duggan and Dr. Zanganeh may be deemed to have acquired beneficial ownership of the securities held by the other spouse upon their marriage on December 18, 2024. Mr. Duggan does not hold any voting or investment power over such securities held by Dr. Zanganeh. Mr. Duggan disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.
(5)		Includes (a) shares owned by Mahin Zanganeh, Dr. Zanganeh’s mother, (b) shares are owned by Mahshad Zanganeh, Dr. Zanganeh’s sister, and (c) shares held in trust for the benefit of an immediate family member. The number of shares of common stock beneficially owned by Dr. Zanganeh as reported in the table above does not include the 48,801,396 shares of common stock which are beneficially owned by Dr. Zanganeh’s spouse, Mr. Duggan, and which are described in footnote 4 above. As spouses, Dr. Zanganeh and Mr. Duggan may be deemed to have acquired beneficial ownership of the securities held by the other spouse upon their marriage on December 18, 2024. Dr. Zanganeh does not hold any voting or investment power over such securities held by Mr. Duggan. Dr. Zanganeh disclaims beneficial ownership of all such securities, except to the extent of her pecuniary interest therein.

Plan category	Number of securities to be issued upon exercise of outstanding options, warrants and rights (a)		Weighted average exercise price of outstanding options, warrants and rights ($)		Number of securities remaining available for future issuance under equity compensation plans excluding securities reflected in column (a)
Equity compensation plans approved by security holders⁽¹⁾		11,561,228		11.44		2,067,021
Equity compensation plans not approved by security holders⁽²⁾		1,525,060		15.12		2,304,109

(1)		Includes the following plans: the 2017 Equity Incentive Plan (the “Equity Incentive Plan”) and the 2017 Employee Stock Purchase Plan (the “ESPP”). Our Equity Incentive Plan provides that the number of shares available for issuance thereunder will be increased on the first day of each fiscal year beginning with the 2018 fiscal year in an amount equal to the least of (i) 1,200,000 shares, (ii) 4% of the outstanding shares of our common stock as of December 31 of the immediately preceding year, or (iii) such number of shares as determined by our Board of Directors. On January 1, 2024, the number of shares available for issuance under the Equity Incentive Plan increased by 1,200,000 shares pursuant to these provisions. On January 1, 2025, the number of shares available for issuance under the Equity Incentive Plan increased by an additional 1,200,000 shares pursuant to the Equity Incentive Plan’s provisions. On September 30, 2025, the number of shares available for issuance under the Equity Incentive Plan increased by 2,000,000 additional shares pursuant to an amendment to the Incentive Plan, which the Company’s stockholders approved at a special meeting. Excluded from the table above is an increase of 1,200,000 additional shares on January 1, 2026, pursuant to the Equity Incentive Plan's provisions. Our ESPP provides that the number of shares available for issuance thereunder will be increased on the first day of each fiscal year beginning with the 2018 fiscal year in an amount equal to the least of (i) 450,000 shares, (ii) 1.5% of the outstanding shares of our common stock as of December 31 of the immediately preceding year, or (iii) such number of shares as determined by our Board of Directors. In December 2022, our Board of Directors elected not to permit an increase to the number of shares available for issuance under our ESPP. However, on January 1, 2024, the number of shares available for issuance under the ESPP increased by 450,000 shares pursuant to the ESPP’s provisions. On January 1, 2025, the number of shares available for issuance under the ESPP increased by an additional 450,000 shares pursuant to the ESPP's provisions. These increases are reflected in the table above. Excluded from the table above is an increase of 450,000 additional shares on January 1, 2026, pursuant to the ESPP's provisions.
(2)		Consists of the Company’s 2017 Inducement Equity Incentive Plan (the “Inducement Plan”), which was adopted by our Board of Directors. We initially reserved 1,000,000 shares of our common stock for issuance pursuant to equity awards granted under the Inducement Plan. On May 20, 2021, the Board approved an amendment to the Inducement Plan to increase the number of shares reserved for issuance by an additional 1,000,000 shares. This increase is reflected in the table above. In March 2024, the Board approved a second amendment to the Inducement Plan to reserve an additional 2,000,000 shares of the Company’s common stock for issuance pursuant to the Inducement Plan. This increase is also reflected in the table above.

Fee Category	2025		2024
Audit Fees	$	860	$	700
Audit-related Fees		205		252
Tax Fees		—		33
All Other Fees		64		56
Total	$	1,129	$	1,041

Exhibit		Incorporation by Reference
Number	Exhibit Description	Form	File No.	Exhibit(s)	Filing Date
2.1	Plan of Conversion of Pulse Biosciences, Inc.	8-K12B	001-37744	2.1	June 18, 2018
3.1	Articles of Conversion	8-K12B	001-37744	3.1	June 18, 2018
3.2	Certificate of Conversion	8-K12B	001-37744	3.2	June 18, 2018
3.3	Certificate of Incorporation of Pulse Biosciences, Inc.	8-K12B	001-37744	3.3	June 18, 2018
3.4	Bylaws of Pulse Biosciences, Inc.	8-K12B	001-37744	3.4	June 18, 2018
4.1	Specimen Common Stock Certificate	8-K12B	001-37744	4.1	June 18, 2018
4.2	Form of Warrant	S-3	333-278494	4.3	April 3, 2024
4.3	Form of Warrant Agent Agreement	S-3	333-278494	4.4	April 3, 2024
10.1	Lease for facilities at 3955 Point Eden Way, Hayward, California, dated January 26, 2017	10-K	001-37744	10.1	March 20, 2017
10.2+	Employment Agreement between Mitchell E. Levinson and the Registrant	10-K	001-37744	10.4	March 31, 2022
10.3+	Employment Agreement between Kevin Danahy and the Registrant	10-K	001-37744	10.5	March 31, 2022
10.4	Securities Purchase Agreement, dated February 7, 2017, by and between Pulse Biosciences, Inc. and certain purchasers	8-K	001-37744	10.1	February 10, 2017
10.5	Securities Purchase Agreement, dated September 24, 2017, by and between Pulse Biosciences, Inc. and certain purchaser	8-K	001-37744	10.1	September 25, 2017
10.6+	2015 Stock Incentive Plan	S-1	333-208694	10.2	December 22, 2015
10.7+	2017 Inducement Equity Incentive Plan and forms of agreements thereunder	8-K	001-37744	10.1	November 28, 2017
10.8+	2017 Equity Incentive Plan and forms of agreements thereunder	10-K	001-37744	10.10	March 12, 2021
10.9+	2017 Employee Stock Purchase Plan and forms of agreements thereunder	8-K	001-37744	10.2	May 19, 2017
10.10+	Executive Employment Agreement between Darrin R. Uecker and the Registrant	S-1	333-208694	10.9	December 22, 2015
10.11+	Amendment to Employment Agreement between Darrin R. Uecker and Pulse Biosciences, Inc. dated October 5, 2016	8-K	001-37744	10.1	October 11, 2016
10.12+	Form of At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement for Employees	S-1	333-208694	10.10	December 22, 2015
10.13+	Form of Indemnification Agreement	8-K12B	001-37744	10.1	June 18, 2018
10.14	First Amendment to the lease for facilities at 3955 Point Eden Way , Hayward, California, dated May 28, 2019	8-K	001-37744	10.19	May 31, 2019
10.15	Securities Purchase Agreement, dated June 30, 2021, by and between Pulse Biosciences, Inc. and Robert W. Duggan	8-K	001-37744	10.1	July 1, 2021
10.16+	Amendment to Employment Agreement, between Darrin Uecker and Pulse Biosciences, Inc., dated September 20, 2022	8-K	001-37744	10.2	September 23, 2022
10.17+	Amendment to Employment Agreement, between Kevin Danahy and Pulse Biosciences, Inc., dated September 23, 2022	8-K	001-37744	10.1	September 28, 2022
10.18+	Amendment to Employment Agreement, between Kevin Danahy and Pulse Biosciences, Inc., dated May 4, 2023	8-K	001-37744	10.1	May 5, 2023
10.19+	Amendment to Employment Agreement, between Darrin Uecker and Pulse Biosciences, Inc., dated May 5, 2023	8-K	001-37744	10.2	May 5, 2023
10.20+	Third Amendment to Employment Agreement, between Kevin Danahy and Pulse Biosciences, Inc., dated March 2024	10-K	001-37744	10.26	March 28, 2024
10.21+	Fourth Amendment to Employment Agreement, between Darrin Uecker and Pulse Biosciences, Inc., dated March 2024	10-K	001-37744	10.27	March 28, 2024
10.22+	Employment Agreement between Paul A. LaViolette and the Registrant	8-K	001-37744	10.1	January 13, 2025
10.23+	Employment Agreement between Jon Skinner and the Registrant	8-K	001-37744	10.1	February 4, 2025
10.24+	Equity Distribution Agreement, dated February 19, 2026, by and between Pulse Biosciences, Inc. and TD Securities (USA) LLC.	8-K	001-37744	1.1	February 19, 2026
19.1*	Insider Trading Policy
21.1	List of Subsidiaries	10-K	001-37744	21.1	March 31, 2025
23.1	Consent of Independent Registered Public Accounting Firm	10-K	001-37744	23.1	March 31, 2025
31.1*	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350).	10-K	001-37744	32.1	March 31, 2025
32.2	Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350).	10-K	001-37744	32.2	March 31, 2025
97.1+	Section 10D Clawback Policy	10-K	001-37744	97.1	March 28, 2024
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

	* Filed herewith
	+ Indicates a management contract or compensatory plan or arrangement.
	# Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a grant of confidential treatment.

	PULSE BIOSCIENCES, INC.
	By:	/s/ Jon Skinner
Date: April 30, 2026		Jon Skinner, Chief Financial Officer
		(Principal Financial Officer)

Amendment: SEC Form 10-K/A filed by Pulse Biosciences Inc